ENTRY       D09325                      Drug
NAME        Blinatumomab (USAN/INN);
            Blinatumomab (genetical recombination) (JAN);
            Blincyto (TN)
PRODUCT     BLINCYTO (Amgen)
FORMULA     C2367H3577N649O772S19
EXACT_MASS  54052.5286
MOL_WEIGHT  54085.8484
REMARK      Therapeutic category: 4291
            ATC code: L01FX07
            Product: D09325<JP/US>
EFFICACY    Antineoplastic, Anti-CD19 and CD3 antibody
  DISEASE   B-cell precursor acute lymphoblastic leukemia (Philadelphia chromosome-negative) [DS:H00001]
  TYPE      Monoclonal antibody, bispecific antibody
TARGET      CD19 [HSA:930] [KO:K06465]
            CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]
  PATHWAY   hsa04660(915+916+917)  T cell receptor signaling pathway
            hsa04662(930)  B cell receptor signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX07 Blinatumomab
                  D09325  Blinatumomab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Blinatumomab
                D09325  Blinatumomab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D09325  Blinatumomab (USAN/INN); Blinatumomab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD3
                 D09325  Blinatumomab (USAN/INN) &lt;JP/US&gt;
                CD19
                 D09325  Blinatumomab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09325
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09325
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09325
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09325
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D09325
DBLINKS     CAS: 853426-35-4
            PubChem: 96026005
///
